Market Place
Sourcing Support
Hutchmed Announces Launch by Takeda of FRUZAQLA in Japan
21 Nov 2024 //
GLOBENEWSWIRE
Hutchmed Highlights Clinical Data at 2024 ASH & ESMO Asia
05 Nov 2024 //
GLOBENEWSWIRE
HUTCHMED to Receive Milestone Payment for FRUZAQLA® Sales
31 Oct 2024 //
GLOBENEWSWIRE
HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer
16 Oct 2024 //
GLOBENEWSWIRE
HUTCHMED Announces Japan Approval For FRUZAQLA By Takeda
23 Sep 2024 //
GLOBENEWSWIRE
HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
08 Sep 2024 //
GLOBENEWSWIRE
Eli Lilly Partner Hutchmed Scraps China Stomach Cancer Filing
31 Aug 2024 //
FIERCE PHARMA
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
29 Aug 2024 //
GLOBENEWSWIRE
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
21 Aug 2024 //
GLOBENEWSWIRE
HUTCHMED Reports 2024 Interim Results and Provides Business Updates
31 Jul 2024 //
GLOBENEWSWIRE
Hutchmed`s NDA For Tazemetostat In Follicular Lymphoma Accepted In China
03 Jul 2024 //
GLOBENEWSWIRE
HUTCHMED to Announce 2024 Half-Year Financial Results
26 Jun 2024 //
GLOBENEWSWIRE
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
24 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED Phase III ESLIM-01 Results Published In Lancet Haematology
16 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED Initiates Phase 1 Trial Of Menin Inhibitor In China
06 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED`s FRUTIGA Phase III Results Published In Nature Medicine
02 Jun 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
23 May 2024 //
GLOBENEWSWIRE
HUTCHMED Announces Chairman Retirement, Appointments & Committee Changes
17 May 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024
16 May 2024 //
GLOBENEWSWIRE
Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib
16 May 2024 //
PHARMABIZ
HUTCHMED, Hengrui Phase 2/3 Pancreatic Cancer Trial Begins
13 May 2024 //
GLOBENEWSWIRE
HUTCHMED Initiates RAPHAEL Phase 3 AML Trial In China
13 May 2024 //
GLOBENEWSWIRE
HUTCHMED Appoints Director, Board Committee Member
08 May 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
05 Apr 2024 //
GLOBENEWSWIRE
HUTCHMED & Innovent NDA Acceptance in China for Fruquintinib with Sintilimab
01 Apr 2024 //
GLOBENEWSWIRE
China NMPA accepts for review Hutchmed’s sNDA for savolitinib
29 Mar 2024 //
PHARMABIZ
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment of NSCLC
27 Mar 2024 //
GLOBENEWSWIRE
HUTCHMED Initiates ESLIM-02 Phase II/III Trial of Sovleplenib in China
21 Mar 2024 //
GLOBENEWSWIRE
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
28 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib
06 Feb 2024 //
GLOBENEWSWIRE
Inmagene Exercises Option to Obtain Worldwide License for IMG-007 and IMG-004
02 Feb 2024 //
PR NEWSWIRE
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates
02 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED to Announce 2023 Final Results
01 Feb 2024 //
GLOBENEWSWIRE
HUTCHMED Receives ELUNATE (fruquintinib) Marketing Approval in Hong Kong
29 Jan 2024 //
GLOBENEWSWIRE
Hutchmed Announces NDA Acceptance in China for Sovleplenib
10 Jan 2024 //
GLOBENEWSWIRE
HUTCHMED has Completed Enrollment of Ph II/III of Fruquintinib with Sintilimab
12 Dec 2023 //
GLOBENEWSWIRE
HUTCHMED Announces Continued Inclusion of ELUNATE and SULANDA
12 Dec 2023 //
GLOBENEWSWIRE
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia
30 Nov 2023 //
GLOBENEWSWIRE
Fruquintinib Becomes First Antineoplastic Drug to Be Prescribed in US
17 Nov 2023 //
YICAIGLOBAL
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
16 Oct 2023 //
GLOBENEWSWIRE
HUTCHMED Announces Submission of New Drug Application for Fruquintinib
29 Sep 2023 //
GLOBENEWSWIRE
HUTCHMED Highlights Presentation of Results from Phase IIIb Trial of Savolitinib
12 Sep 2023 //
GLOBENEWSWIRE
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat
11 Sep 2023 //
GLOBENEWSWIRE
HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
29 Aug 2023 //
PRESS RELEASE
HUTCHMED Receives Breakthrough Therapy China for Savolitinib for Gastric Cancer
28 Aug 2023 //
GLOBENEWSWIRE
HUTCHMED Announces that Sovleplenib PIII ESLIM-01 Study Met Its Primary Endpoint
21 Aug 2023 //
GLOBENEWSWIRE
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
31 Jul 2023 //
GLOBENEWSWIRE
Hutchmed Receives BTD for Fruquintinib Combination with Sintilimab
19 Jul 2023 //
GLOBENEWSWIRE
HUTCHMED Announces Changes to Board of Directors and Technical Committee
13 Jul 2023 //
GLOBENEWSWIRE
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415
07 Jul 2023 //
GLOBENEWSWIRE
HUTCHMED to Announce 2023 Half-Year Financial Results
26 Jun 2023 //
GLOBENEWSWIRE
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
15 Jun 2023 //
PRESS RELEASE
HUTCHMED Highlights Presentations for Hematological Malignancy Programs
09 Jun 2023 //
GLOBENEWSWIRE
Takeda wins priority review for $400M colorectal drug, licensed from Hutchmed
26 May 2023 //
ENDPTS
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
25 May 2023 //
GLOBENEWSWIRE
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib
25 May 2023 //
GLOBENEWSWIRE
HUTCHMED Announces Board of Directors and Board Committee Membership
12 May 2023 //
GLOBENEWSWIRE
HUTCHMED Announces Appointment of Independent Non-executive Director
10 May 2023 //
GLOBENEWSWIRE
HUTCHMED Announces NDA Acceptance in China for Fruquintinib
17 Apr 2023 //
GLOBENEWSWIRE
